Wave Life Sciences announced that it has commenced an underwritten public offering of $100M in aggregate of its ordinary shares, and, to certain investors that so choose in lieu of ordinary shares, pre-funded warrants to purchase ordinary shares. All of the securities in the offering will be sold by Wave Life Sciences. J.P. Morgan and Leerink Partners are acting as joint book-running managers for the offering.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on WVE:
- Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
- Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
- Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
- Wave Life Sciences reports Q3 EPS 7c, consensus (18c)
- Is WVE a Buy, Before Earnings?